News
ARWR
22.22
-4.43%
-1.03
Weekly Report: what happened at ARWR last week (0902-0906)?
Weekly Report · 21m ago
The past three years for Arrowhead Pharmaceuticals (NASDAQ:ARWR) investors has not been profitable
Simply Wall St · 2d ago
Arrowhead Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $60 Price Target
Benzinga · 3d ago
Arrowhead Pharmaceuticals (ARWR) Receives a Buy from TD Cowen
TipRanks · 4d ago
Hold Rating on Arrowhead Pharmaceuticals Amid Promising Clinical Data and Upcoming Regulatory Hurdles
TipRanks · 4d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 5d ago
Arrowhead’s Plozasiran Shows Promise Amidst Competition and Operational Concerns: Maintaining Hold Rating
TipRanks · 5d ago
Arrowhead Pharmaceuticals’ Plozasiran: A Promising Treatment for FCS with Strong Market Potential
TipRanks · 5d ago
Arrowhead Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Dow Jones · 5d ago
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $60 Price Target
Benzinga · 5d ago
Strong Buy Rating for Arrowhead Pharmaceuticals’ Plozasiran Based on Positive Clinical Trial Outcomes and Market Potential
TipRanks · 5d ago
Why Arrowhead Pharmaceuticals Is Rising In Pre-market?
NASDAQ · 5d ago
Arrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for Plozasiran
Dow Jones · 5d ago
ARROWHEAD PHARMACEUTICALS <ARWR.O>: LEERINK PARTNERS RAISES TARGET PRICE TO $20 FROM $19
Reuters · 5d ago
U.S. RESEARCH ROUNDUP-Commercial Metals, M&T Bank, Simon Property
Reuters · 6d ago
Arrowhead's Plozasiran Meets All Primary and Secondary Endpoints in Phase 3 Study, To Seek FDA Approval
Benzinga · 6d ago
Arrowhead Pharmaceuticals: Strong Buy Rating on Robust Clinical Data and Promising Commercial Prospects
TipRanks · 6d ago
Weekly Report: what happened at ARWR last week (0826-0830)?
Weekly Report · 09/02 09:12
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
Barchart · 09/02 05:36
More
Webull provides a variety of real-time ARWR stock news. You can receive the latest news about Arrowhead Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.